You just read:

European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO™ (venetoclax) Monotherapy for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia

News provided by

AbbVie

08 Dec, 2016, 06:00 GMT